Can we cure 50% of all multiple myeloma patients in the next five years?
Immunotherapy for the treatment of multiple myeloma
Expanding role for MRD in managing MM
ENDEAVOUR, ASPIRE and TOURMALINE-MM1 trial results for multiple myeloma
Understanding the drivers behind disease with the 100,000 Genomes Project